Systemic co-delivery of doxorubicin and siRNA using nanoparticles conjugated with EGFR-specific targeting peptide to enhance chemotherapy in ovarian tumor bearing mice

Journal of Nanoparticle Research

Volumn 15, Issue 10, 2013, Pages

  Liu, C W ^a,b   Lin, W J ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

Author keywords

Doxorubicin; Epidermal growth factor receptor; Heptapeptide; Nanoparticles; siRNA

Indexed keywords

CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; MAMMALS; MOLECULES; NANOPARTICLES; PEPTIDES; POLYETHYLENE GLYCOLS; TUMORS;

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTORS; HEPTAPEPTIDES; INTRACELLULAR ACCUMULATION; OVARIAN CANCER CELLS; POLY(D , L-LACTIC-CO-GLYCOLIC ACID); SIRNA; THERAPEUTIC AGENTS;

TARGETED DRUG DELIVERY;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HEPTAPEPTIDE; MACROGOL; NANOCARRIER; NANOCONJUGATE; POLYGLACTIN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER INHIBITION; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG SPECIFICITY; DRUG UPTAKE; ENDOCYTOSIS; FEMALE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY TUMOR; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR CELL LINE; ZETA POTENTIAL;

EID: 84887010960     PISSN: 13880764     EISSN: 1572896X     Source Type: Journal    
DOI: 10.1007/s11051-013-1956-z     Document Type: Article

References (43)

1. Beletsi A, Panagi Z, Avgoustakis K (2005) Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers. Int J Pharm 298:233-241 (Pubitemid 40828344)
2. Burnett JC, Rossi JJ (2012) RNA-based therapeutics: current progress and future prospects. Chem Biol 19:60-71
3. Burnett JC, Rossi JJ, Tiemann K (2011) Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 6:1130-1146
4. Chen Y, Bathula SR, Li J, Huang L (2010) Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem 285:22639-22650
5. Chittasupho C, Xie SX, Baoum A, Yakovleva T, Siahaan TJ, Berkland CJ (2009) ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur J Pharm Sci 37:141-150
6. Choi SK, Verma M, Silpe J, Moody RE, Tang K, Hanson JJ, Baker JR Jr (2012) A photochemical approach for controlled drug release in targeted drug delivery. Bioorg Med Chem 20:1281-1290
7. Couvreur P, Vauthier C (2006) Nanotechnology: intelligent design to treat complex disease. Pharm Res 23:1417-1450 (Pubitemid 43993807)
8. Filmus J, Pollak MN, Cailleau R, Buick RN (1985) MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem Biophys Res Commun 128:898-905 (Pubitemid 15000428)
9. Gilabert-Estelles J, Braza-Boils A, Ramon LA, Zorio E, Medina P, Espana F, Estelles A (2012) Role of microRNAs in gynecological pathology. Curr Med Chem 19:2406-2413
10. Gillies ER, Frechet JM (2005) pH-Responsive copolymer assemblies for controlled release of doxorubicin. Bioconjug Chem 16:361-368 (Pubitemid 40388212)
11. Guo AVSJ, Jozsef Varga MZ, Leung PCK (2010) Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway. Reprod Biol Endocrinol 8:11
12. Hillaireau H, Couvreur P (2009) Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 66:2873-2896
13. Huang M, Ma Z, Khor E, Lim LY (2002) Uptake of FITC-chitosan nanoparticles by A549. Pharm Res 19:1488-1494
14. Itabashi H, Maesawa C, Oikawa H, Kotani K, Sakurai E, Kato K, Komatsu H, Nitta H, Kawamura H, Wakabayashi G, Masuda T (2008) Angiotensin II and epidermal growth factor receptor cross-talk mediated by a disintegrin and metalloprotease accelerates tumor cell proliferation of hepatocellular carcinoma cell lines. Hepatol Res 38:601-613 (Pubitemid 351622286)
15. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC (2012) Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 41:2971-3010
16. Khoee S, Rahmatolahzadeh R (2012) Synthesis and characterization of pH-responsive and folated nanoparticles based on self-assembled brush-like PLGA/PEG/AEMA copolymer with targeted cancer therapy properties: a comprehensive kinetic study. Eur J Med Chem 50:416-427
17. Kneidinger D, Ibrisimovic M, Lion T, Klein R (2012) Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery. Antiviral Res 94:195-207
18. Kundu AK, Chandra PK, Hazari S, Pramar YV, Dash S, Mandal TK (2012) Development and optimization of nanosomal formulations for siRNA delivery to the liver. Eur J Pharm Biopharm 80:257-267
19. Lamy PJ, Jacot W (2012) Worldwide variations in EGFR somatic mutations: a challenge for personalized medicine. Diagn Pathol 7:13
20. Lehtinen J, Raki M, Bergstrom KA, Uutela P, Lehtinen K, Hiltunen A, Pikkarainen J, Liang H, Pitkanen S, Maatta AM, Ketola RA, Yliperttula M, Wirth T, Urtti A (2012) Pre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinoma. PLoS One 7:e41410
21. Liu CW, Lin WJ (2012) Polymeric nanoparticles conjugate a novel heptapeptide as an active targeting ligand for doxorubicin. Int J Nanomedicine 7:4749-4767
22. Liu Q, Xiao L, Yuan D, Shi X, Li P (2012) Silencing of the integrin-linked kinase gene induces the apoptosis in ovarian carcinoma. J Recept Signal Transduct Res 32:120-127
23. Maeda H (2010) Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 21:797-802
24. Mendoza-Espinoza JA, Campos-Lara M (2011) Cytotoxic evaluation of fluvastatin and rosuvastatin and effect of fluvastatin in the hela cell cycle. Afri J Pharm Pharmacol 5:322-326
25. Milella M, Nuzzo C, Bria E, Sperduti I, Visca P, Buttitta F, Antoniani B, Merola R, Gelibter A, Cuppone F, D'Alicandro V, Ceribelli A, Rinaldi M, Cianciulli A, Felicioni L, Malatesta S, Marchetti A, Mottolese M, Cognetti F (2012) EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. J Thorac Oncol 7:672-680
26. Modjtahedi H, Komurasaki T, Toyoda H, Dean C (1998) Anti-EGFR monoclonal antibodies which act as EGF, TGF alpha, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours. Int J Cancer 75:310-316 (Pubitemid 28100075)
27. Rahman MA, Amin AR, Wang X, Zuckerman JE, Choi CH, Zhou B, Wang D, Nannapaneni S, Koenig L, Chen Z, Chen ZG, Yen Y, Davis ME, Shin DM (2012) Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth. J Control Release 159:384-392
28. Reinehr R, Haussinger D (2012) CD95 death receptor and epidermal growth factor receptor (EGFR) in liver cell apoptosis and regeneration. Arch Biochem Biophys 518:2-7
29. Shen Y (2008) Advances in the development of siRNA-based therapeutics for cancer. Drugs 11:572-578
30. Shirako E, Hirayama N, Tsukada Y, Tanaka T, Kitamura N (2008) Up-regulation of p21CIP1 expression mediated by ERK-dependent and -independent pathways contributes to hepatocyte growth factor-induced inhibition of HepG2 hepatoma cell proliferation. J Cell Biochem 104:176-188
31. Shroff K, Kokkoli E (2012) PEGylated liposomal doxorubicin targeted to alpha5beta1-expressing MDA-MB-231 breast cancer cells. Langmuir 28:4729-4736
32. Song S, Liu D, Peng J, Deng H, Guo Y, Xu LX, Miller AD, Xu Y (2009) Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo. FASEB J 23:1396-1404
33. Stanislaus A, Bakhtiar A, Salleh D, Tiash S, Fatemian T, Hossain S, Akaike T, Chowdhury E (2012) Knockdown of PLC-gamma-2 and calmodulin 1 genes sensitizes human cervical adenocarcinoma cells to doxorubicin and paclitaxel. Cancer Cell Int 12:30
34. Tahara K, Sakai T, Yamamoto H, Takeuchi H, Kawashima Y (2008) Establishing chitosan coated PLGA nanosphere platform loaded with wide variety of nucleic acid by complexation with cationic compound for gene delivery. Int J Pharm 354:210-216
35. Tahara K, Yamamoto H, Hirashima N, Kawashima Y (2010) Chitosan-modified poly(d,l-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects. Eur J Pharm Biopharm 74:421-426
36. Tian XH, Wei F, Wang TX, Wang P, Lin XN, Wang J, Wang D, Ren L (2012) In vitro and in vivo studies on gelatin-siloxane nanoparticles conjugated with SynB peptide to increase drug delivery to the brain. Int J Nanomedicine 7:1031-1041
37. Xue HY, Wong HL (2011) Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization. Biomaterials 32:2662-2672
38. Yu B, Tai HC, Xue W, Lee LJ, Lee RJ (2010) Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol 27:286-298
39. Zajchowski DA, Karlan BY, Shawver LK (2012) Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas. Mol Cancer Ther 11:492-502
40. Zampros I, Praidou A, Brazitikos P, Ekonomidis P, Androudi S (2012) Antivascular endothelial growth factor agents for neovascular age-related macular degeneration. J Ophthalmol 2012:319728
41. Zhao S, Ma D, Dai H, Yuan F, Wang Z (2011) Biologically inhibitory effects of VEGF siRNA on endometrial carcinoma cells. Arch Gynecol Obstet 284:1533-1541
42. Zhou J, Gan N, Zhang W, Lu W, Xie X (2010) Proliferation suppression and apoptosis of ovarian carcinoma cells induced by small interfering RNA against vascular endothelial growth factor. J Obstet Gynaecol Res 36:232-238
43. Zhu YF, Gao GL, Tang SB, Zhang ZD, Huang QS (2013) Effect of WFDC 2 silencing on the proliferation, motility and invasion of human serous ovarian cancer cells in vitro. Asian Pac J Trop Med 6:265-272